NHS patients will lose access to new cutting-edge treatments because of skyrocketing costs, the pharmaceutical giant Novartis ...

Novartis has bet up to $772 million to gain access to BioArctic’s BrainTransporter platform, which was leveraged in a ...

For potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed target in neurodegeneration ...

BioArctic partners with Novartis to develop neurodegenerative treatments using BrainTransporter tech. Read more here.

Health innovation is reshaping Vietnam, with Novartis Vietnam’s Karina Ng highlighting efforts to expand patient access to ...

In the heat of the CDK4/6 market showdown, Eli Lilly has notched an overall survival win to back Verzenio’s case against ...

Novartis is putting down $30 million, with a potential $772 million on the line, to work with BioArctic’s tech to find a new ...

The Atypical Hemolytic Uremic Syndrome market is expected to surge due to the disease's increasing prevalence and awareness ...

Novartis has reported that its experimental drug ianalumab met the primary goal in a phase 3 trial for primary immune ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a potential new ...

Ianalumab has a dual mechanism of action, B-cell depletion and BAFF-R inhibition, and is being investigated across various B ...